1 Spiroperidol binding (dopamine D2 receptors) and quinuclidinyl benzilate binding (muscarinic receptors) in striata of 19-month old mice was analyzed for animals that had received chronic administration of cytidine 5'-diphosphocholine (CDP-choline) incorporated into the chow consumed (100 or 500 mg kg-1 added per day) for the 7 months before they were killed. 2 Treated animals displayed an increase in the dopamine receptor densities of 11% for those receiving l00mgkg-I and 18% for those receiving 500mgkg -as compared to the control aged animals that had received no CDP-choline. Control animals showed, from 2 months to 19 months of life, a 28% decrease in the receptor density. No change in the affinity of the receptors for spiroperidol was found in the treated or untreated animals. 3 Muscarinic acetylcholine receptor densities were also partially recovered by the same treatment in aged animals that showed a 14% decrease of these receptors in this case. The muscarinic receptor density increased 6% for the animals that received 100mgkg-and 17% for the animals that received 500 mg kg'-without any change in the affinity of the receptor for quinuclidinyl benzilate. 4 Aged animals displayed a slight increase in brain membrane fluidity as indicated by a decrease in the polarization value of the non-polar fluorophore 1,6-diphenyl-1,3,5-hexatriene. Interestingly, in the treated animals a greater increase in membrane fluidity was determined and found to be very similar for the two doses. 5 It is concluded that chronic administration of CDP-choline to aged animals promoted a partial recovery of the striatum dopamine and acetylcholine receptor function normally reduced with aging, which might be explicable in terms of mechanisms involving fluidity of the brain neuronal membrane.
Introduction
Cytidine 5'-diphosphocholine (CDP-choline) has been widely used for the treatment of different diseases of the central nervous system (Manaka et al., 1974; Salvadorini et al., 1975; Cohadon et al., 1982; Lecuire & Duplay, 1982) . Membrane diffusion of this compound, after intravenous or oral administration, requires splitting of the molecule into CMP and phosphocholine, which are later metabolized to cytidine and choline (Yashima et al., 1975; Lopez-G. Coviella et al., 1987) . These two major circulating products are then incorporated into their respective cellular pools and their increased concentrations would account for the pharmacological properties of CDP-choline.
Choline, as phosphocholine, is a precursor in the synthesis of phosphatidylcholine (PC), and cytidine, as CTP, is also an intermediary in the synthesis of PC and other membrane phospholipids. Administration of CDP-choline reportedly affects brain phospholipid biosynthesis (Dorman et al., 1983) , membrane structure (Horrocks et al., 1981) and, both in vitro and in vivo, the metabolism and release of certain brain and peripheral neurotransmitters (Martinet et al., 1981; Agut et al., 1984; Lopez-G. Coviella et al., 1986) .
The question of how neurotransmitter binding can be affected by this treatment seemed of primary importance in understanding the mechanisms of the pharmacological action of CDP-choline. Some reported therapeutic effects of choline donors on several diseases that go together with aging such as Parkinson's disease (Agnoli et al., 1982 ), Huntington's chorea (Growdon et al., 1977) or Alzheimer's disease (Etienne et al., 1979) , focused our attention on the neurotransmitters dopamine and acetylcholine as good markers of possible neurotransmission changes in these cases. Several authors have reported that the density of either dopamine receptors Author for correspondence. (Marquis et al., 1981; Morgan et al., 1987) or muscarinic cholinoceptors (Biegon et al., 1988) decreases with aging of animals without any change in affinity. Morgan et al. (1987) have found that the decrease in dopamine receptor density is mostly found in the D2 type, which led us to analyze a D2 ligand such as spiroperidol. Furthermore, in man, Seeman et al. (1987) have reported a decrease of D1 and D2 dopamine receptors of 3.2% and 2.2% per decade respectively.
It has been shown that the phospholipid content of various regions of the human brain diminishes with age and that the cholesterol content displays, in these same samples, an even more dramatic decrease that results in a decrease in the cholesterol/phospholipid ratio (Soderberg et al., 1990) . In another context, measurements of phosphatidylethanolamine, phosphatidylcholine and phosphatidylserine have been shown to increase by 15% to 20% in membrane preparations of aging mice treated with CDP-choline (Lopez-G. Coviella et al., 1988) . These changes in the lipid composition of the membrane may cause modifications in the membrane fluidity according to descriptions of several authors, showing that methylation of membrane phospholipids affect the membrane fluidity (Mio et al., 1984) .
In this context it seemed of interest to determine in aging animals the effect of the administration of CDP-choline on the possible modulation of the number of receptors as well as on their brain membrane fluidity.
Methods

Animals
Female CD-1 mice were housed at constant room temperature (21°C), relative humidity (60%) and with 12:12 h light:dark cycle, with free access to food and water. At 12 months of age animals were assigned randomly to one of three .-) Macmillan Press Ltd, 1991 dietary groups and fed either regular (Omgkg-1day-'), or CDP-choline supplemented 100mg or 500mg kg-1 day -) chow for another 7 months. From the average animal weight and food intake, amounts of CDP-choline to be added to the diet were calculated to adjust a mean dose and the adjustment was repeated every two weeks. A group of young animals consisting of untreated two month-old mice kept under the same conditions were used for comparison. The group of aged animals fed with the regular diet was used as control animals.
Tissue preparation
Mice were decapitated, and the corpus striatum was immediately removed and immersed in 50mM Tris-HCI buffer (pH 7.1) containing (mM): NaCl 120, KCI 5, Ca2Cl 2, MgCl2 1 and pargyline 10pUM. The striatum of each mouse was homogenized in 2 ml of buffer for 15s with a Polytron (PCU Kinematica Model GmbH) at setting 7. The homogenate was then centrifuged at 27,000g for 20min and the pellet resuspended in the same volume of buffer, and centrifuged twice more. The final pellet was resuspended in 2.5 ml of the same buffer.
When the preparation was used for the measurement of membrane fluidity, cerebral hemispheres were homogenized in 2ml of 10mM Tris-HCI (pH 7.4) and the homogenate centrifuged at 12,000g for 30min. The pellet was discarded and the supernatant centrifuged at 48,000g for 30 min. The pellet, resuspended in the homogenizing buffer, was used as plasma membrane fraction for use in fluidity measurements.
Binding assay
The D2 receptor densities were measured by saturating the tissue with increasing concentrations of [3H]-spiroperidol. The binding of [3H]-spiroperidol was determined by a modification of the assay described by Leysen et al. (1978 
Results
Spiroperidol binding
Our reference values of spiroperidol binding of striata showed, as has already been reported (Morgan et al., 1987) , clear differences between the groups of young and old animals. In our experimental conditions the receptor density of old animals presented a significant 28% decrease (P < 0.01) compared to the value obtained with young animals (Table 1 ). The Kd displayed a slightly increased value for the old animals as compared to the young ones (non-significant).
The Bmax values obtained with treated animals always lay between the reference values of the young and old animals. As shown in Table 1 , the average value determined for the group of animals treated with 100mg kg-' of CDP-choline was 11% higher than that of the group of non-treated aged animals. The average value for the group of animals treated with 500mgkg-' was even higher, with an increase reaching 18% of the average value corresponding to the group of nontreated aged animals. This second value differed significantly (P < 0.02) from that of the aged control group. The average values of the Kd for both groups of treated animals were slightly higher than the average values found for both groups of untreated animals (old and young); however, the differences were not statistically significant.
Quinuclidinyl benzilate binding
Our results indicated that the difference in binding between old and young mice is smaller for QNB than for spiroperidol. The decrease, although statistically significant (P < 0.01), was in this case a mere 14% (Table 2) . The values of Kd determined for QNB, as those found for spiroperidol, did not differ significantly, displaying a slight increase.
The data obtained with the treated aged animals followed the same trends as were found for spiroperidol. Thus the treatment of aged animals with CDP-choline at 100mgkg-increased the Bmax by 6% while treatment with 500mgkg-1 increased the Bmax by 17%; in this second case with a high statistical significance (P < 0.02). The average value of Kd corresponding to either of the two groups of treated animals dis- played no difference when compared to the reference value of the non-treated animals (Table 2 ).
Membranefluidity
Studies of brain membrane fluidity were performed by measuring the polarization changes of the non-polar fluorophore DPH used as a probe in our membrane preparations. Membrane fluidity for old animals was shown to be slightly higher than that corresponding to membranes of young animals as indicated by the decrease of 0.55 in the steady state polarization value (Table 3) . Chronic administration of CDP-choline clearly diminished the polarization and hence increased the membrane fluidity. The values determined differed significantly from those of the aged control animals regardless of the dose administered, with a change of 1.13 (P < 0.02) for the animals treated with 100mgkg-1 of CDP-choline and a change of 1.08 (P < 0.005) for the animals treated with 500mg kg-'. No clear distinction could be established between the two groups of treated animals, which had a very close polarization average value.
Discussion
Phospholipid methylation and PC membrane enrichment has been correlated with increases in fl-adrenoceptors by Hirata & Axelrod (1980) . Increase in receptor densities by administration of CDP-choline has also been reported for the cholinergic system in young animals (Petkov & Popova, 1987) . In this paper we demonstrate that D2 dopamine receptor densities, as indicated by the spiroperidol binding, which are nor- mally reduced with aging (Seeman et al., 1987; Morgan et al., 1987) are partially recovered by administration of a choline and cytidine donor such as CDP-choline, known to increase the membrane levels of PC (Lopez-G. coviella et al., 1988) . Similarly, the decline in muscarinic cholinoceptors also found with aging is clearly blunted by CDP-choline treatment.
In the two cases studied, changes in receptor densities as a consequence of CDP-choline administration seemed not to affect the affinity constant of the receptor for their ligands, which is consistent with the fact that in general, aging induced a decrease in receptor densities without any change in affinity (Pradhan, 1980) . Thus, CDP-choline treatment seems to improve the dopamine receptor and also the muscarinic cholinoceptor function through increases in the receptor number.
With the information available to date, it has been difficult to propose a molecular mechanism to explain this phenomenon, especially for the simultaneous effect on both systems. Some authors have tried to assign the parallel modification of dopamine and choline receptors by CDP-choline administration to a specific mechanism of increase in dopamine content of the striatum after treatment, which would cause a decline in the acetylcholine content leading to an increase in the cholinoceptor densities (Petkov & Popova, 1987) . The observations described here of spiroperidol and QNB binding modification could also be explained by a less specific effect of the membrane structure on the receptor function, either through receptor availability or through changes in receptor conformation (Loh & Law, 1980; Henis, 1989) .
It is well known that in most of the regions of the human brain, including the striatum, the phospholipid content declines with age and that cholesterol declines even more, resulting in an important decrease in the cholesterol to phospholipid ratio (Sbderberg et al., 1990) . It has also been shown that the decrease in cholesterol content of the membranes enhances their fluidity (Wilson et al., 1988) . Therefore, aging would lead to an increase in membrane fluidity, as is indicated by our experiments showing a lower polarization value (higher membrane fluidity) for the old animals compared to the young animals. As CDP-choline administration increases brain phospholipid content (Lopez-G. Coviella et al., 1988) , the cholesterol to phospholipid ratio would also decrease with the corresponding membrane fluidity increase (see Table 3 ). How these changes in membrane structure modify receptor function cannot be unambiguously explained at present. It should be borne in mind that receptor density measurements are a consequence of receptor number and optimal receptor structure and that the interaction of membrane phospholipids and proteins with receptor protein may affect receptor mobility as well as receptor structure.
Chronic treatment of aged mice with CDP-choline recovers the reduced density of dopamine and acetylcholine receptors of the striatum. This beneficial effect of the choline donor might perhaps be related, through more or less complex mechanisms, to an increase in brain membrane fluidity observed in these animals.
